What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...
CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound ... over 30 years with ...
Instead, according to Bourla, Pfizer aims to get into the obesity market through either orals or injectables with a different mechanism of action from semaglutide-based treatments like Wegovy and ...
If your BMI (Body Mass Index) lands in the obesity range, Zepbound could be a viable solution. It may also be a possible solution if you’re dealing with weight-related issues like high blood pressure, ...
In these cases, your healthcare professional may recommend an alternative, such as Wegovy, Zepbound ... they don’t have the same mechanisms of action as Ozempic. There is no over-the-counter ...
Mounjaro: Also contains tirzepatide and shares the same mechanism of action as Zepbound. Dr Zara Dadi, medical cosmetologist, aesthetician, and anti-aging specialist tells India Today that Mounjaro ...